Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Maviret

Maviret 100 mg/40 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9–10

HOS-139040 · Präparat HOS-098268

9  therapeutic drug monitoring of tacrolimus is recommended and a dose adjustment of tacrolimus made accordingly. PROTON PUMP INHIBITORS Omeprazole ↓ glecaprevir 0.78 0.71 -- No dose 20 mg once daily (0.60, (0.58, 0.86) adjustment is 1.00) required. (Increase gastric ↔ ↔ ↔ -- pH value) pibrentasvir Omeprazole ↓ glecaprevir 0.36 0.49 -- 40 mg once daily (0.21, (0.35, 0.68) (1 hour before 0.59) breakfast) ↔ ↔ ↔ -- pibrentasvir Omeprazole ↓ glecaprevir 0.54 0.51 -- 40 mg once daily (0.44, (0.45, 0.59) (evening without 0.65) food) ↔ ↔ ↔ -- pibrentasvir VITAMIN K ANTAGONISTS Vitamin K Not studied. Close monitoring antagonists of INR is recommended with all vitamin K antagonists. This is due to liver function changes during treatment with Maviret. DAA=direct acting antiviral a. Effect of rifampicin on glecaprevir and pibrentasvir 24 hours after final rifampicin dose. b. Effect of atazanavir and ritonavir on the first dose of glecaprevir and pibrentasvir is reported. c. HCV-infected transplant recipients who received a median ciclosporin dose of 100 mg per day had increased glecaprevir exposures to 2.4-fold of those not receiving ciclosporin.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atazanavir (HOS-086180) vitamin K (HOS-091176) tacrolimus (HOS-085202) ritonavir (HOS-084521) omeprazole (HOS-085912)